Cargando…

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis

OBJECTIVES: To compare drug survival in patients with axial spondyloarthritis treated with different TNF inhibitors in standard dosage. METHODS: Patients fulfilling the Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis in the Swiss Clinical Qua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hebeisen, Monika, Scherer, Almut, Micheroli, Raphael, Nissen, Michael J., Tamborrini, Giorgio, Möller, Burkhard, Zufferey, Pascal, Exer, Pascale, Ciurea, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542531/ https://www.ncbi.nlm.nih.gov/pubmed/31145730 http://dx.doi.org/10.1371/journal.pone.0216746

Ejemplares similares

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
por: Micheroli, Raphael, et al.
Publicado: (2017)

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry
por: Ciurea, Adrian, et al.
Publicado: (2023)

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort
por: Neuenschwander, Regula, et al.
Publicado: (2020)

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort
por: Hebeisen, Monika, et al.
Publicado: (2020)

Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry
por: Micheroli, Raphael, et al.
Publicado: (2022)

HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry
por: Fröhlich, Fabienne, et al.
Publicado: (2022)

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort
por: Ciurea, Adrian, et al.
Publicado: (2022)

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry
por: Ciurea, Adrian, et al.
Publicado: (2023)

Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years
por: Ensslin, Caroline, et al.
Publicado: (2023)

Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry
por: Popova, Vjara, et al.
Publicado: (2023)

Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry
por: Micheroli, Raphael, et al.
Publicado: (2023)

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
por: Ciurea, Adrian, et al.
Publicado: (2016)

Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort
por: Micheroli, Raphael, et al.
Publicado: (2022)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors
por: Nissen, Michael J., et al.
Publicado: (2021)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
por: Soubrier, Martin, et al.
Publicado: (2018)

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis
por: Paccou, Julien, et al.
Publicado: (2016)

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
por: Molnar, Christoph, et al.
Publicado: (2018)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials
por: Toussirot, Eric, et al.
Publicado: (2016)

Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Publicado: (2021)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials [Corrigendum]
Publicado: (2017)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Validation of assessment methods for the apparent diffusion coefficient in a clinical trial of axial spondyloarthritis patients treated with golimumab
por: Møller, Jakob M., et al.
Publicado: (2020)

Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
por: Baker, Rahaf, et al.
Publicado: (2018)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021)

Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years
por: Möller, Burkhard, et al.
Publicado: (2020)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab
por: Otsuka, Akiyo, et al.
Publicado: (2015)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
por: Lanz, Sofia, et al.
Publicado: (2021)

Chronische Rückenschmerzen bei axialer Spondyloarthritis: Aktuelle diagnostische Herausforderungen und therapeutische Möglichkeiten
por: Möller, Burkhard
Publicado: (2022)

Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients
por: Lin, Zhiming, et al.
Publicado: (2015)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cs7p4rm6r8efr9l2tb45sqmsmu